The NLRP3 inflammasome rs35829419 C>A polymorphism is associated with type 2 diabetes mellitus in Saudi Arabia

References

1. 1.↵
   1. Al Mansour MA.

   The prevalence and risk factors of type 2 diabetes mellitus (T2DM) in a semi-urban Saudi population. Int J Environ Res Public Health 2019; 17: 7.

   OpenUrl
2. 2.↵
   1. Tsalamandris S,
   2. Antonopoulos AS,
   3. Oikonomou E,
   4. Papamikroulis GA,
   5. Vogiatzi G,
   6. Papaioannou S, et al.

   The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol 2019; 14: 50–59.

   OpenUrl
3. 3.↵
   1. Galicia-Garcia U,
   2. Benito-Vicente A,
   3. Jebari S,
   4. Larrea-Sebal A,
   5. Siddiqi H,
   6. Uribe KB, et al.

   Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 2020; 21: 6275.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Zheng D,
   2. Liwinski T,
   3. Elinav E.

   Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov 2020; 6: 36.

   OpenUrl
5. 5.↵
   1. Xu J,
   2. Núñez G.

   The NLRP3 inflammasome: activation and regulation. Trends Biochem Sci 2023; 48: 331–344.

   OpenUrl
6. 6.↵
   1. Kelley N,
   2. Jeltema D,
   3. Duan Y,
   4. He Y.

   The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci 2019; 20: 3328.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Lu S,
   2. Li Y,
   3. Qian Z,
   4. Zhao T,
   5. Feng Z,
   6. Weng X, et al.

   Role of the inflammasome in insulin resistance and type 2 diabetes mellitus. Front Immunol 2023; 14: 1052756.

   OpenUrl
8. 8.↵
   1. Poznyak A,
   2. Grechko AV,
   3. Poggio P,
   4. Myasoedova VA,
   5. Alfieri V,
   6. Orekhov AN.

   The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci 2020; 21: 1835.

   OpenUrlPubMed
9. 9.↵
   1. Lu F,
   2. Chen H,
   3. Hong Y,
   4. Lin Y,
   5. Liu L,
   6. Wei N, et al.

   A gain-of-function NLRP3 3’-UTR polymorphism causes miR-146a-mediated suppression of NLRP3 expression and confers protection against sepsis progression. Sci Rep 2021; 11: 13300.

   OpenUrl
10. 10.↵
    1. Wang Z,
    2. Zhang S,
    3. Xiao Y,
    4. Zhang W,
    5. Wu S,
    6. Qin T, et al.

    NLRP3 inflammasome and inflammatory diseases. Oxid Med Cell Longev 2020; 2020: 4063562.

    OpenUrl
11. 11.↵
    1. Zhang Q,
    2. Fan HW,
    3. Zhang JZ,
    4. Wang YM,
    5. Xing HJ.

    NLRP3 rs35829419 polymorphism is associated with increased susceptibility to multiple diseases in humans. Genet Mol Res 2015; 14: 13968–13980.

    OpenUrlCrossRef
12. 12.↵
    1. Cirillo E,
    2. Kutmon M,
    3. Gonzalez Hernandez M,
    4. Hooimeijer T,
    5. Adriaens ME,
    6. Eijssen LMT, et al.

    From SNPs to pathways: biological interpretation of type 2 diabetes (T2DM) genome wide association study (GWAS) results. PLoS One 2018; 13: e0193515.

    OpenUrlCrossRefPubMed
13. 13.↵
    SNPedia. [Updated 2022: Accessed 2023 Feb 18]. Available from: https://www.snpedia.com/index.php/Rs35829419%5
14. 14.↵
    1. Gora IM,
    2. Ciechanowska A,
    3. Ladyzynski P.

    NLRP3 inflammasome at the interface of inflammation, endothelial dysfunction, and type 2 diabetes. Cells 2021; 10: 314.

    OpenUrl
15. 15.↵
    1. Zhou R,
    2. Tardivel A,
    3. Thorens B,
    4. Choi I,
    5. Tschopp J.

    Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11: 136–140.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Cordero MD,
    2. Alcocer-Gómez E,
    3. Ryffel B.

    Gain of function mutation and inflammasome driven diseases in human and mouse models. J Autoimmun 2018; 91: 13–22.

    OpenUrlCrossRef
17. 17.↵
    1. Liwei Bai MC,
    2. Qianqian Zhai, Di Wang,
    3. Jie Hai, Sumei Jin,
    4. Qinggui Zhang

    . Association of two common SNPs in NLRP3 with risk of type 2 diabetes mellitus and their interaction with environmental factors. Int J Clin Exp Pathol 2016; 9: 10499–10506.

    OpenUrl
18. 18.↵
    1. Menini S,
    2. Iacobini C,
    3. Vitale M,
    4. Pugliese G.

    The inflammasome in chronic complications of diabetes and related metabolic disorders. Cells 2020; 9: 1812.

    OpenUrl
19. 19.↵
    1. Sun Q,
    2. Wang C,
    3. Yan B,
    4. Shi X,
    5. Shi Y,
    6. Qu L, et al.

    Jinmaitong ameliorates diabetic peripheral neuropathy through suppressing TXNIP/NLRP3 inflammasome activation in the streptozotocin-induced diabetic rat model. Diabetes Metab Syndr Obes 2019; 12: 2145–2155.

    OpenUrl
20. 20.↵
    1. Kuo CY,
    2. Maran JJ,
    3. Jamieson EG,
    4. Rupenthal ID,
    5. Murphy R,
    6. Mugisho OO.

    Characterization of NLRP3 inflammasome activation in the onset of diabetic retinopathy. Int J Mol Sci 2022; 23: 14471.

    OpenUrl
21. 21.↵
    1. Lee J.

    Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance, and type 2 diabetes. Arch Pharm Res 2013; 36: 208–222.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Javaid HMA,
    2. Ko E,
    3. Joo EJ,
    4. Kwon SH,
    5. Park JH,
    6. Shin S, et al.

    TNFα-induced NLRP3 inflammasome mediates adipocyte dysfunction and activates macrophages through adipocyte-derived lipocalin 2. Metabolism 2023; 142: 155527.

    OpenUrl
23. 23.↵
    1. Wani K,
    2. AlHarthi H,
    3. Alghamdi A,
    4. Sabico S,
    5. Al-Daghri NM.

    Role of NLRP3 inflammasome activation in obesity-mediated metabolic disorders. Int J Environ Res Public Health 2021; 18: 511.

    OpenUrl